

Weiterführende Literatur

- Bandelow B.: Panik und Agoraphobie. Diagnose, Ursachen, Behandlung. Springer, Wien, New York 2001.
- Bandelow B et Michaelis S.: Epidemiology of anxiety disorders in the 21st century. *Dialogues Clin Neurosci* 2015; 17(3):327–35.
- Bandelow B. et al.: Deutsche S3-Leitlinie Behandlung von Angststörungen. www.awmf.org/leitlinien.html (2014)
- Bandelow B et al.: Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. *International Journal of Psychiatry in Clinical Practice* 2012; 16 (2): 77–84
- Lee DJ et al.: Psychotherapy versus pharmacotherapy for PTSD: systemic review and meta-analysis to determine first line treatment. *Depress Anxiety* 2016; 33(9):792–806.
- De Lijster JM et al.: The age of onset of anxiety disorders: a meta-analysis. *Can J Psychiatry* 2017; 62(4):237–246.
- Kasper S et Montgomery S.: Treatment-resistant depression. Chichester: Wiley-Blackwell (2013)
- Kessler RC et al.: Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. *Int J Methods Psychiatr Res* 2012; 21(3):169–84.
- Kraus C et al.: Administration of ketamine for unipolar and bipolar depression. *International Journal of Psychiatry in Clinical Practice* 2017; 21:2–12
- Schosser A et al.: European Group for the Study of Resistant Depression (GSRD) - where have we gone so far: review of clinical and genetic findings. *European Neuropsychopharmacology* 2012; 22 (7): 453–468
- Wittchen HU et Jacobi F: Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies. *Eur Neuropsychopharmacol* 2005; 15(4):357–76.